New combo therapy aims to wipe out breast cancer before surgery
NCT ID NCT04373031
First seen Dec 12, 2025 · Last updated May 16, 2026 · Updated 14 times
Summary
This study tests whether adding an extra immunotherapy drug at the start of standard treatment can help the immune system better attack triple negative breast cancer before surgery. About 12 adults with untreated, locally advanced TNBC will receive either standard chemo plus pembrolizumab or that same regimen with an additional immunotherapy primer. The main goal is to see how many patients have no cancer left at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.